Skip to main content

Table 4 Cox multivariable models for time to progression and overall survival a

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

    Time to progression     Overall survival   
Risk factor n HR 95% CI   P HR 95% CI   P
Regimen (GD vs. D)   0.60 (0.42- 0.84) 0.003 0.88 (0.67- 1.15) 0.34
TIMP-1 (positive vs. negative)   0.82 (0.55- 1.21) 0.31 0.71 (0.52- 0.98) 0.03
PAM50      0.007     0.0001
  Luminal A 78 0.68 (0.45- 1.04) 0.08 0.78 0.56 1.08 0.14
  Luminal B 100b 1.00 referent    1.00 referent   
  Basal-like 40 1.75 (1.05- 2.92) 0.03 2.39 (1.56- 3.64) <0.0001
  HER2-enriched 46 1.30 (0.82- 2.07) 0.27 1.25 (0.85- 1.84) 0.25
Visceral disease (yes vs. no)   1.60 (1.07- 2.39) 0.02 1.13 (0.84- 1.53) 0.42
Stage of disease (locally advanced vs. metastatic) 1.96 (1.02- 3.76) 0.04 0.72 (0.42- 1.24) 0.23
Metastatic sites (3+ vs. 1-2)   1.24 (0.86- 1.77) 0.25 1.52 (1.13- 2.04) 0.01
ECOG performance status (2 vs. 0-1)   1.19 (0.85- 1.67) 0.31 1.47 (1.12- 1.93) 0.006
  1. aModels stratified for previous chemotherapy (none, n = 76; adjuvant, n = 86; locally advanced or metastatic, n = 102).
  2. bIncluding 6 records with missing value of PAM50 molecular subtype.
  3. Abbreviations: CI Confidence interval, D Docetaxel, ECOG Eastern Cooperative Oncology Group, G Gemcitabine, HER2 Human epidermal growth factor receptor 2, HR Hazard ratio, TIMP-1 Tissue inhibitor of metalloproteinases-1.